Oncology Precision Medicine Market

Market Size

The oncology precision medicine market, valued at USD 166 billion in 2025, is project to reach USD 185 billion in 2026 and USD 364 billion by 2035, representing a CAGR of 7.8% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of cancer targeted, the blood / hematologic cancer segment holds the highest share (~25%) of the market.
• With regards to route of administration, the intravenous route of administration segment dominates the global market.
• Based on the type of molecule, the biologics segment holds the largest market share (nearly 60%) in 2026.
• With respect to drug class, kinase inhibitor captures the highest share (53%) in 2026.
• In terms of key geographical regions, North America captures the majority of the market share. Notably, Asia-Pacific is anticipated to grow at a faster pace in the near future.

Market Overview

Cancer is recognized as one of the deadliest diseases due to the high prevalence and mortality rates across the globe. According to the World Health Organization, in the year 2020, the global cancer burden was estimated to be 20 million new cases and 10 million deaths, annually, and is anticipated to rise by nearly 60%, by 2040. The key factors contributing to the growing prevalence and pathogenesis of cancer include alcohol intake, obesity, viral infections, radiation and chemical exposure.

Currently, there are several conventional approaches, including surgery, radiation therapy, and chemotherapy that are used for the treatment of cancer. In addition, there are several nonconventional or complementary therapeutic methods that are being employed in cancer treatment, such as hormone therapy, immunotherapy and nanotherapy. However, these approaches have been found to be incompetent for dealing with intrinsic carcinogenic genetic abnormalities, which can arise from patient-specific mutations in oncogenes, tumor suppressor genes and DNA repair genes.

In order to address abovementioned limitation of existing treatment options, the concept of precision medicine, often known as personalized medicine, has emerged as a possible solution, which utilizes genomic knowledge to develop gene-targeted therapeutics.

The development process of precision medicine involves the study of tumor features, genetic data, lifestyle of patients and environmental effects to provide tailored medicines, which hold significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach. Individuals with a family history of certain types of cancer are more likely to be at risk of inheriting the condition.

In such cases, precision oncology aids individuals to take genetic testing and become aware of the associated risk. Further, prior screening for cancer can help in detection of the disease at an early stage, providing a much better chance of successful treatment.

It is worth highlighting that there are number of precision cancer centers, such as MD Anderson Cancer Center in US, Memorial Sloan Kettering Cancer Center in New York and Mayo Clinic Cancer Center in US, that offer advanced technologies and treatments that are suitable for patients with rare or difficult-to-treat cancers. Further, the oncology precision medicines have shown high efficiency during clinical trials due to which the participation of volunteers in such trials has increased. This has resulted in a higher patient pool in clinical trials, helping the researchers in better decision making for the evaluated drug or technology. With continuous research efforts and innovation in this field, it is anticipated that the adoption of such targeted drugs will increase significantly, driving the oncology precision medicine market growth during the forecast period.

Oncology Precision Medicine Market Trends

• Increase in Partnership: The partnerships have enabled the stakeholders to enhance their existing capabilities and drug portfolios, and strengthen their presence in the oncology precision medicine domain. Drug licensing agreements, clinical trial agreements, and research and development agreements are the most common types of partnerships signed by stakeholders in the precision medicine in oncology domain. Most of these partnerships are focused on targeting cancers, including gastrointestinal cancer (23%), lung cancer (23%), hematologic cancer and breast cancer (15%, each).
• Clinical Trial Activity: There has been a notable rise in the number of clinical trials evaluating precision medicines for oncology. Around 6,500 clinical trials related to precision medicine in oncology have been registered in the past six years, indicating the substantial research in this domain. Among these, about 60% of these clinical trials are actively recruiting to evaluate drugs for various types of cancer targeted.

Industry Experts

The oncology precision medicine market report features detailed transcripts of interviews held with the following industry stakeholders (arranged on the basis of designation):

• Chief Scientific Officer and Founder, Very Small Company, US
• Vice President, Mid-sized Company, US

Market Share Insights

Market Share by Target Cancer

• This section includes segment of oncology precision medicine market based on target cancer, including bladder cancer, blood / hematologic cancer, breast cancer, cervical cancer, gastrointestinal cancer, head and neck squamous cell cancer, lung cancer, skin cancer and others.
• Among these the blood / hematologic cancer holds the maximum share (~55%) in the current precision oncology market. This can be attributed to the high incidence of blood / hematologic cancer, accounting for around 1.25 million cases worldwide per year.
• As per our precision oncology market analysis, gastrointestinal cancer is estimated to grow at the highest CAGR (>10%) till 2035.

Market Share by Drug Class

• This segment includes the segmentation of global oncology precision medicine market across different drug classes, such as kinase inhibitors, enzyme inhibitors, immune checkpoint inhibitors and others.
• The kinase inhibitor drug class segment occupies the highest share and is expected to witness substantial growth in the coming years. It is worth noting that majority of kinase inhibitors target mutated protein growth factors, such as EGFR and FGFR.

Market Share by Key Geographical Regions

• It is worth highlighting that North America captures 42% of the current total oncology precision medicine market. Further, oncology precision medicine market in Asia-Pacific is expected to grow with a CAGR of more than 14.37%.
• This can be attributed to the fact that Asian countries, including China, Japan, Korea and India have a growing economy, and thus require low-cost investment for conducting clinical trials. Further, several investments and initiatives taken by government authorities in the Asian countries promote the oncology precision medicine market.
• The detailed methodology across the global oncology precision medicine market and revenue generated across various segments is available in the full report.

Key Market Insights

Competitive Landscape of Oncology Precision Medicine Developers

The oncology precision medicine is among the most promising domains in the healthcare industry. Currently, over 125 precision medicine oncology companies are involved in developing various personalized medicines for oncology. In addition, around 145 personalized medicines have been commercialized for targeting various cancer indications. Further, more than 100 personalized medicines targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development.

Market Segmentation Insights

Frequently Asked Questions